From the helm: Argenica Therapeutics (ASX:AGN), Dr. Liz Dallimore, CEO & MD Artwork

The Bellcast

Bridge the investing and markets knowledge gap with the Bell Direct Bellcast. From bite-size thought snippets, to full length interviews with the top executives of leading ASX200 companies, you'll be informed and ready for any market movement.

All Episodes

The Bellcast

From the helm: Argenica Therapeutics (ASX:AGN), Dr. Liz Dallimore, CEO & MD

October 01, 2025

0:00 | 11:42

Join Bell Financial Group's Senior Market Analyst Grady Wulff as she sat down with Dr. Liz Dallimore, CEO & MD of Argenica Therapeutics (ASX:AGN) to discuss the company's lead drug candidate ARG-007, and its pathway to commercialisation to become the world's first neuroprotective drug for the protection of brain cells post stroke or catastrophic brain injury.

In this interview, Liz covers:

• (0:40) an overview of Argenica Therapeutics (ASX:AGN)

• (1:28) details on ARG-007, including its mechanism in protecting brain cells after stroke

• (4:59) expected runway, and potential need for additional financing pre-Phase 3

• (8:42) other drug candidates in development within Argenica’s pipeline

• (10:01) expected investor news flow over the next 12 months

Note: This interview was filmed on 24 September 2025.